Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

Patricia Pérez-Galán,¹,² Martin Dreyling,³ Adrian Wiestner¹

¹ Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
² IDIBAPS, University of Barcelona, Spain
³ Dept. of Medicine III, Klinikum der Universität München - Campus Grosshadern, Germany

Short title: MCL in the genomic era

Correspondence:
Adrian Wiestner
Hematology Branch, NHLBI, NIH
Bld 10, CRC 3-5140
10 Center Drive
20892-1202 Bethesda, MD
phone: (301) 594 6855
fax: (301) 496 8396
e-mail: wiestnea@nhlbi.nih.gov
Abstract

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma of which at least a subset arises from antigen experienced B-cells. However, what role antigen stimulation plays in its pathogenesis remains ill defined. The genetic hallmark is the chromosomal translocation t(11;14) resulting in aberrant expression of cyclin D1. Secondary genetic events increase the oncogenic potential of cyclin D1, and frequently inactivate DNA damage response pathways. In combination these changes drive cell cycle progression and give rise to pronounced genetic instability. Several signaling pathways contribute to MCL pathogenesis including the often constitutively activated PI3K/AKT/mTOR pathway, which promotes tumor proliferation and survival. WNT, Hedgehog, and NF-κB pathways also appear to be important. While MCL typically responds to frontline chemotherapy, it remains incurable with standard approaches. Proteasome inhibitors (bortezomib), mTOR inhibitors (temsirolimus) and IMIDS (lenalidomide) have recently been added to the treatment options in MCL. The molecular basis for the anti-tumor activity of these agents is an area of intense study that hopefully will lead to further improvements in the near future. Given its unique biology, relative rarity, and the difficulty in achieving long lasting remissions with conventional approaches, patients with MCL should be encouraged to participate in clinical trials.
Diagnosis, clinical course, and the origin of MCL

Mantle cell lymphoma (MCL), a mature B-cell neoplasm defined as a distinct entity in the early 1990s constitutes about 6% of all non-Hodgkin’s lymphomas (NHL). MCL is typically disseminated at presentation, with a leukemic component in 20-30% of patients. Classic and blastoid variants are recognized, the latter associated with inferior clinical outcome (Figure 1A). The genetic hallmark of MCL is the translocation t(11;14)(q13;q32) leading to aberrant expression of cyclin D1, which is not typically expressed in normal lymphocytes (Figure 1B). However, cyclin D1 negative cases having typical morphology and gene expression profile have been described and often show overexpression of cyclin D2 or D3. Recently, SOX11 has been described as a diagnostic marker that is equally expressed in D1-positive and D1-negative MCL. MCL is one of the most difficult to treat B-cell lymphomas. While conventional chemotherapy induces high remission rates in previously untreated patients, relapse within a few years is common, contributing to a rather short median survival of 5-7 years. The best predictor of survival is tumor proliferation (Figure 1C). Intensification of first line treatment has improved progression free survival but no curative regimen has been defined so far.

In MCL, as in chronic lymphocytic leukemia (CLL), the variable region of the expressed immunoglobulin heavy chain gene (IgVH) displays either germline configuration (Ig-unmutated), as found in naïve B-cells or contains somatic mutations (Ig-mutated), indicating a response to antigen. In CLL, the presence or absence of somatic mutations identifies two disease subtypes with divergent clinical outcome. In contrast, in MCL, the prognostic role of the IgVH mutation status has not been confirmed. However, a subset of leukemic MCL cases that are characterized by minimal nodal involvement and a relatively indolent course often belong to the Ig-mutated subtype. Absence of SOX11 expression has recently been identified as a characteristic feature of this indolent subtype.

MCL has been thought to originate from naïve, pre-germinal center (GC) lymphocytes. However, several observations suggest that this is not always the case. MCL cells show biased use of certain IgVH genes, especially VH3-21, VH3-23, VH4-34, and VH4-59 and up to 40% of cases show somatic mutations of the IgVH gene. Mutations are frequent in VH3-23 and VH4-59 genes and often occur in so called hotspot regions. VH3-21 is almost exclusively found in germline configuration and is commonly paired with the light chain IGLV3-19. Many VH3-21 expressing tumors show virtually identical amino acid sequences in the CDR3 region. Interestingly, the structure of the VH3-21 CDR3 region differs...
between MCL and CLL suggesting a different antigen specificity of the BCR in these two malignancies.\textsuperscript{15} Combined, these findings indicate that at least a subset of MCL, similar to CLL, is derived from antigen experienced B-cells. In keeping with this notion is the expression of genes that code for chemokine receptors involved in trafficking after initial B-cell activation.\textsuperscript{16} Furthermore, almost half of MCL cases express one or more immunohistochemical marker characteristic of a GC or post-GC phenotype, in particular IRF4.\textsuperscript{17} In rare cases plasma cell differentiation of the clonal cells has been reported.\textsuperscript{18, 19} A partial plasmacytic phenotype characterized by relatively stronger CD38 and IRF4 expression is more common and can identify a biologically distinct subset of MCL.\textsuperscript{20}

**Cyclin D1, at the center of MCL pathogenesis**

Whether the t(11;14) translocation and the resultant aberrant expression of cyclin D1 is the initiating event in the pathogenesis is difficult to ascertain but likely given its key role in MCL biology and its continued importance for tumor proliferation and clinical outcome.\textsuperscript{21} The \textit{CCND1} gene consists of 5 exons, which can be alternatively spliced to cyclin D1a and D1b isoforms (Figure 1D). In most cases cyclin D1a and D1b mRNAs are coexpressed. However, D1b protein is not consistently detected,\textsuperscript{22} and its contribution, if any, to MCL pathogenesis remains elusive. Cyclin D1a contains a long 3’UTR region harboring mRNA destabilizing elements that limit its half life to approximately 30 minutes.\textsuperscript{21} In addition, miR15/16 can bind the 3’UTR and inhibit cyclin D1 translation.\textsuperscript{23, 24} Abundant cyclin D1a transcripts that lack the full-length 3’UTR are commonly found in highly proliferative tumors and predict short survival.\textsuperscript{21} Genomic deletions and point mutations in the 3’UTR give rise to these short cyclin D1a transcripts that are more stable than the full-length mRNA. In addition, the truncation removes the miR binding sites. Combined these additional events enhance the influence of the t(11;14) by generating higher and prolonged cyclin D1 mRNA and protein expression resulting in higher tumor proliferation and shorter survival of MCL patients.\textsuperscript{21}

Cyclin D1a, a 30kDa labile protein forms a complex with the cyclin dependent kinase CDK4 or CDK6 to promote cell cycle entry (Figure 2). Both of these CDKs are often overexpressed in MCL. The \textit{CDK4} locus is frequently amplified,\textsuperscript{25} and decreased expression of miR-29, which targets CDK6, can lead to increased CDK6 expression and identifies patients with short survival.\textsuperscript{26} Transcription, translation, assembly into holoenzyme complexes, subcellular localization and degradation of cyclin D1 are tightly regulated. While
overexpression of cyclin D1 is not transforming in nude mice, additional events that increase nuclear cyclin D1 levels enhance its oncogenic potential. Mutation of threonine 268 to alanine (T286A) prevents phosphorylation by GSK3β thereby inhibiting cyclin D1 nuclear export. This mutant protein is potently transforming and induces a mature B-cell lymphoma in transgenic mice. In the cytoplasm cyclin D1 is polyubiquitinated by the E3 ligase SCF(FBX4-αB Crystallin) and degraded through the proteasome. The T268A mutation and mutations in the E3 ubiquitin ligase complex increase nuclear cyclin D1 expression and have been detected in solid tumors. While no such mutations have been described in MCL, PI3K/AKT mediated inhibition of GSK3β could have a similar effect and contribute to cyclin D1 dysregulation in MCL.

**Genetic instability and the role of DNA damage pathways**

MCL is one of the B-cell malignancies with the highest degree of genomic instability and a large number of secondary chromosomal alterations have been described in MCL including losses, gains, and amplifications of chromosomal regions that contain genes involved in cell cycle regulation, DNA damage response pathways, signal transduction and apoptosis (Table 1). Recently, uniparental disomy (UPD) has been described in a large number of cases and contributes to the inactivation of tumor suppressor genes. For example, one of the most commonly detected UPDs involves the chromosomal band 17p and is associated with TP53 inactivation. The origin of the genetic instability of MCL is not clear. However, aberrant re-initiation of DNA replication during S-phase due to cyclinD1/CDK4 induced stabilization of CDT1 could be an important contributor (Figure 2). Re-initiation can generate segmental duplications and copy number variations, which are commonly found in MCL, and may give rise to break prone regions that promote additional chromosomal alterations. Acquired chromosomal aberrations in DNA damage checkpoint genes and in genes related to microtubule dynamics, such as MAP2 and MAP6 can further increase genomic instability.

Secondary genetic alterations that affect DNA damage response pathways are of particular interest, because they may contribute to refractoriness to chemotherapy. 11q22-23 deletions affecting the ATM gene are recurrent in MCL. The ATM kinase is critically involved in the cellular response to DNA damage and may act as a tumor suppressor gene (Figure 3). Truncating or missense mutations involving the PI3K domain of ATM are found in a majority of MCL cases and are commonly accompanied by the loss of the other allele. The
high frequency of \textit{ATM} mutations in MCL is striking and has been linked to \textit{ATM} expression in naïve B-cells in the mantle zone. Another mechanism for the strong selective pressure on \textit{ATM} mutant clones may be aberrant re-initiation of DNA replication during S-phase leading to double strand DNA breaks and activation of the \textit{ATM} pathway.\textsuperscript{28} A decrease in expression of CHK1 and CHK2, two serine-threonine kinases downstream of S-phase checkpoints have also been identified in cases of MCL with high chromosomal instability.\textsuperscript{4} The tumor suppressor gene \textit{TP53}, downstream of \textit{ATM}, plays an important role in DNA damage responses. Mutations of \textit{TP53} typically in conjunction with 17p13 deletions have been detected primarily in blastoid MCL cases. An alternative mechanism to disrupt the p53 pathway involves overexpression of the negative regulators MDM2 and MDM4. MDM2 overexpression due to copy number gains correlates with inferior survival. Similarly, MDM4, which is also highly expressed in MCL decreases expression of the CDK inhibitor p21, thereby promoting cell cycle progression.\textsuperscript{33} Recently, high expression of the serine/threonine kinase Pim-1 has been found in MCL. Consistent with the ability of Pim-1 to stabilize MDM2 these tumors overexpress MDM2.\textsuperscript{34}

\textbf{The molecular basis of novel treatment approaches for MCL}

Cyclin D1, cell cycle control and DNA damage pathways have been the centerpiece of research in MCL.\textsuperscript{35} More recently signaling pathways that further enhance tumor proliferation, facilitate evasion of apoptosis, reduce immune control, and promote interactions with the cellular microenvironment have been identified. These include the BCR,\textsuperscript{36, 37} PI3K/AKT/mTOR,\textsuperscript{38-41} NF-κB,\textsuperscript{42-44} TNF,\textsuperscript{36, 42} Hedgehog,\textsuperscript{45} and WNT pathways,\textsuperscript{5, 40, 46} and the BCL-2 family of apoptosis regulators.\textsuperscript{42, 47} Agents targeting these pathways may provide new therapeutic options (Table 2).

\textbf{Proteasome inhibitors}

The ubiquitin-proteasome system, the major non-lysosomal pathway through which intracellular proteins are degraded, exhibits three proteolytic activities: chymotrypsin- (CT-L), trypsin- (T-L) and caspase-like (C-L), each localized to a distinct 20S proteasome beta subunit. Bortezomib, a peptide boronic acid that reversibly inhibits primarily the CT-L activity is the first proteasome inhibitor approved by the FDA. Phase II clinical trials of single agent bortezomib demonstrated durable responses in 33-58\% of patients with relapsed or
Bortezomib is now increasingly combined with other agents. Interestingly, some studies suggest a sequence-dependent synergism with chemotherapy. The mechanism how bortezomib acts as an anti-cancer agent has been intensely investigated and may differ between disease entities. The initial hypothesis that bortezomib exerts its cytotoxic effect through inhibition of NF-κB signaling is not supported by recent studies, at least not in Multiple Myeloma (MM) and MCL. The discovery that bortezomib induces apoptosis in MCL through upregulation of the BH3-only protein NOXA revealed a direct proapoptotic mechanism. NOXA acts as a downstream effector of an integrated cellular stress response triggered by the accumulation of undegraded, polyubiquitinated proteins that induce endoplasmic reticulum (ER) stress and the generation of reactive oxygen species (ROS). Combined this triggers a transcriptional response that prominently involves the transcription factor NRF2, which was significantly stronger in bortezomib sensitive tumors than in tumors of patients with inferior responses. Ultimately, NOXA is induced by two cooperating mechanisms: decreased ubiquitination of histone H2A that facilitates access to the NOXA gene (PMAIP1) promoter, and joint binding of ATF3 and ATF4 which drive its transcription. Finally, NOXA triggers BAK- and BAX-dependent mitochondrial apoptosis.

Recently, gene expression analysis of bortezomib adapted cell lines unexpectedly revealed that bortezomib resistant MCL cells showed partial plasmacytic differentiation, including increased expression of the transcription factor IRF4 and its target genes, and of the cell surface marker CD38 and CD138. In contrast to plasma cells, plasmacytic MCL cells did not increase immunoglobulin secretion. Thus plasmacytic differentiation in the absence of an increased secretory load may enable cells to withstand the stress of proteasome inhibition and lead to bortezomib resistance. This mirrors observations in MM, where high protein secretion sensitizes cells to proteasome inhibitors. Importantly, MCL tumors from patients with inferior clinical responses to bortezomib also had high IRF4 and CD38 expression identifying possible clinical markers of bortezomib resistance.

A second generation of proteasome inhibitors aiming for continued activity against bortezomib-resistant cells, simplified dosing schemes, and reduced toxicity is now entering the clinic. NPI-0052 (salinosporamide A), a natural product related to lactacystin targets all 3 catalytic sites (CT-L, T-L and C-L), provides more potent and more durable proteasome inhibition, and is active against bortezomib resistant MM cells. PR-171 (carfilzomib), a modified peptide related to the natural product epoxymicin, selectively and irreversibly disables the CT-L activity, which may explain its greater cytotoxicity. MLN9708, a second generation peptide boronic acid derivative, hydrolyzes to MLN2238, the biologically active
form that reversibly blocks CT-L activity and has shown preclinical efficacy in hematologic malignancies.61

**Cyclin D1, cell cycle control, and cell cycle inhibitors**

Cyclin D1 and cell cycle control appear as natural targets in MCL. Two basic strategies have been pursued: downregulation of cyclin D1 expression and inhibition of CDK function. PI3K and mTOR inhibitors, can inhibit cyclin D1 translation and promote its degradation (discussed in the section on PI3K/AKT/mTOR), while PD0332991 blocks cell cycle progression through potent inhibition of CDK4/6.22, 62 The pan-CDK inhibitor flavopiridol, whose mechanism of action involves inhibition of RNA synthesis, has minor clinical activity as single agent, but a modified dosing regimen has shown considerable activity in CLL63 and is currently under investigation in MCL.64

**BCR pathway**

Recent studies reported constitutive activation of the BCR signal transduction components SYK and PKCβ II.36, 37 SYK was amplified in both Jeko-1 cells and some primary MCL samples, but constitutive activity of SYK was only demonstrated in the cell line.37 Jeko-1 cells were more sensitive to a SYK inhibitor than MCL cell lines without constitutive SYK activation, indicating some dependence on the pathway. In a screen for phosphoproteins, PKCβ II was found to be phosphorylated in primary MCL samples in contrast to normal B-cells.36 However, it was not localized to lipid rafts as would be expected following classic BCR activation. Inhibitors targeting the signaling cascade downstream of the BCR have entered clinical testing. Fostamatinib, an inhibitor of SYK, achieved a 55% response rate in CLL but only one in nine patients with MCL responded.65 Enzastaurin, a selective PKCβ inhibitor, induced no objective responses in MCL.66 More recently, a phase I study of the BTK inhibitor PCI-32765 reported objective responses in a few patients with MCL.67 Thus, a role for BCR signaling in MCL pathogenesis and the possible clinical benefit of agents targeting this pathway deserve further investigation.

**PI3K/AKT/mTOR pathway**

The PI3K/AKT pathway is involved in the transduction of a variety of extracellular signals and plays a prominent role in many cancers.68 In normal B cells, PI3K functions as a transducer of BCR signaling that regulates proliferation, differentiation, apoptosis, and survival (Figure 4). Gene expression profiling implicated the PI3K/AKT pathway in the
pathogenesis of MCL,\textsuperscript{40} and several key components of the PI3K/AKT/mTOR pathway are activated in MCL,\textsuperscript{69} indicating a possible contribution of this pathway to MCL pathogenesis. Constitutive activation of AKT was found in most blastoid and many classic MCL tumors and was associated with the phosphorylation of downstream targets including MDM2, Bad, and p27.\textsuperscript{39, 41} Furthermore, AKT mediated activation of mTOR and its downstream targets S6K and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) can increase translation of key proteins.

Several mechanisms may cause constitutive activation of AKT, including activation of upstream kinases such as SYK, and amplification of \textit{PI3KCA}, the gene encoding the catalytic subunit p110\textalpha.\textsuperscript{70} In contrast to solid tumors, no activating somatic mutations of \textit{PI3KCA} have been identified.\textsuperscript{41, 70} Loss of PTEN, a phosphatase that turns the PI3K pathway off is another recurrent feature in MCL and may be the result of mutations, deletions, or promoter methylation.\textsuperscript{41} PTEN can also be inactivated by phosphorylation at Ser380 and Thr382/383, which has been found in MCL cases with constitutively active AKT.\textsuperscript{39} The mechanism of PI3K/AKT/mTOR activation can determine the therapeutic potential of small molecule inhibitors. In tumors addicted to an upstream kinase such as SYK, PI3K/AKT signaling can effectively be turned off by inhibition of the upstream kinase. In contrast, in tumors with constitutive activation of PI3K or AKT, inhibitors directed at these kinases may be required.

\textbf{PI3K inhibitors:} The PI3K inhibitor Ly294002 induces p27 accumulation and cyclin D1 downregulation in vitro leading to G1 arrest in MCL cell lines. Eventually, apoptosis ensues likely due to activation of Bad and downregulation of MCL-1 and BCL-X\textsubscript{L}.\textsuperscript{39, 69} Recently, several PI3K isoform specific inhibitors have entered clinical trials in NHL. However, the relative importance of the different PI3K isoforms in MCL pathogenesis is unclear. While PI3K\textsubscript{\delta} is primarily activated by BCR signaling, PI3K\textalpha has been shown to be sufficient to support survival of B-cells with defective BCR signaling.\textsuperscript{71} ON-01910.Na, a styryl sulfone that shows activity against PI3K\textalpha reduced eukaryotic initiation factor 4E (eIF4E)-mediated cyclin D1 mRNA translation and induced apoptosis in MCL cell lines.\textsuperscript{72} CAL-101, a selective PI3K\textsubscript{\delta} inhibitor reduced constitutive and BCR-induced AKT phosphorylation resulting in apoptosis. It also inhibited CXCL12 induced migration of MCL cell lines.\textsuperscript{73} In a phase I pilot study this oral compound achieved remissions in 6 of 7 MCL patients.\textsuperscript{125} Perifosine, a synthetic alkylphospholipid targets the pleckstrin homology domain of Akt, thereby preventing its translocation to the plasma membrane.\textsuperscript{74} It thus inhibits Akt without affecting the activity of PI3K or phosphoinositide-dependent kinase 1 (PDK1). Perifosine has shown
preclinical activity in several cancers including MM\textsuperscript{75} and is now undergoing clinical testing in MM, CLL, and lymphoma including MCL.

**mTOR inhibitors**: The mammalian target of rapamycin (mTOR), a serine-theronine kinase downstream of AKT, forms the complexes, mTORC1 (mTOR-Raptor) and mTORC2 (mTOR-Rictor), which have distinct substrates and mechanisms of activation (Figure 4). The best-known substrates of TORC1 are ribosomal protein S6 and 4E-EBP1. Recent genetic studies in a murine model demonstrated that phosphorylation of 4E-BP1 is a key step in the oncogenic pathway downstream of AKT/mTOR, while phosphorylation of S6 was dispensable.\textsuperscript{76} Phosphorylation of 4E-BP1 leads to its dissociation from eIF4 resulting in increased translation of key proteins including cyclin D1, c-MYC and MCL-1. The main substrate of mTORC2 is AKT.

Rapamycin and its analogs (rapalogs) are allosteric inhibitors of the mTORC1 complex that block some but not all mTORC1 functions and have no effect on mTORC2 (Table 2).\textsuperscript{77} Rapalogs do not induce apoptosis of MCL cells in-vitro,\textsuperscript{78-80} but most studies report induction of Go/G1 arrest. The mechanisms of cell cycle arrest have remained ill defined and effects on cyclin D1 and p27 differ between different studies.\textsuperscript{39, 80} One explanation for this variability could be that GSK-3\textbeta, which promotes nuclear export and proteasomal degradation of cyclin D1, is inactivated by phosphorylation through either AKT or mTOR (Figure 2). Thus, mTOR inhibitors will increase cyclin D1 proteolysis only when inactivation of GSK-3\textbeta is dependent on mTOR but not AKT.\textsuperscript{39}

In a multi center trial temsirolimus was superior to investigator’s choice monochemotherapy in relapsed MCL\textsuperscript{81} and was subsequently approved for this indication by the European Medicines Agency. Clinical responses to rapalogs are mostly PRs in 20-40\% of patients that are of relatively short duration.\textsuperscript{79, 81-83} Analysis of MCL tumor cells from patients during treatment with temsirolimus confirmed reduced S6 phosphorylation. However, there was no correlation to clinical response.\textsuperscript{79} Explanations for the limited clinical activity of rapalogs are increasingly apparent.\textsuperscript{76, 77} Rapalogs inhibit only some mTORC1 functions, and inhibition of S6 phosphorylation, while consistently detected, does not induce apoptosis and has only minimal effects on translation. Furthermore, rapalogs have no effect on mTORC2, which can activate AKT in a negative feedback loop. Thus, mTOR catalytic site inhibitors, which target mTORC1/2 equally, could be more effective.

**NF-κB pathway**
The NF-κB family of transcription factors, (p50/p105, p65/RELA, c-REL, RELB, and p52/p100) binds DNA as hetero- and homo-dimers that activate the transcription of genes involved in survival, proliferation and apoptosis. The canonical pathway is activated through phosphorylation and consequent degradation of IκBα, a cytosolic inhibitor that sequesters p50 and RELA. Constitutive activation of the canonical NF-κB pathway has been reported in MCL cell lines evidenced by the presence of pIκBα and nuclear p65, p50 and c-REL (Figure 4). Gene expression profiling of MCL patient samples revealed frequent high expression of NF-κB target genes that correlated with strong pIκBα expression on tissue microarrays. NF-κB target genes highly expressed in MCL include the antiapoptotic proteins BCL-2, BCL-XL, XIAP, and cFLIP. Activation of the non-canonical pathway (p52, RELB) has been reported in some MCL cell lines (Granta-519, JVM-2 and NCEB), but this could be due to EBV-transformation. BCR engagement and TNF signaling in the lymphoma microenvironment may contribute inducible NF-κB activation. NF-κB signaling can also drive transcription of the TNF family member BAFF/BLyS, a potent B-cell survival factor that binds BAFF-R, BCMA and TACI. BAFF in turn stimulates both canonical and alternative NF-κB pathways, activating a positive feedback loop that could contribute to tumor cell survival. Recently, BAFF-R has been detected in the nucleus of MCL cells, where it co-localized with IKKβ and cooperated in histone H3 phosphorylation. BAFF-R associated with c-REL leading to increase transcription of genes that promote cell survival and proliferation. Constitutive activation of NF-κB signaling may also be caused by the inactivation of TNFAIP3/A20, a ubiquitin editing enzyme that acts as a negative regulator. TNFAIP3/A20 is often inactivated in MCL through genomic deletions, mutations, and increased promoter methylation. Moreover, MCL cases showed mono- and bi-allelic deletions of FAF1, which inhibits p65 and IKKβ.

IKK inhibitors: In keeping with the role of NF-κB in MCL survival inhibitors of this pathway such as BAY-117082, curcumin, or the IKKβ inhibitor BMS-345541, have shown in vitro activity in MCL. However, despite its preclinical promise it has apparently proven difficult to translate this class of compounds into the clinic and except for curcumin no clinical trials of these compounds are currently ongoing.

Proteasome inhibition to block NF-κB signaling: Inhibition of the NF-κB pathway has initially been hypothesized as mechanisms of bortezomib induced apoptosis. However, in MM it has recently been shown that bortezomib efficiently inhibits inducible but not constitutive NF-κB activity and can even cause canonical NF-κB activation.
inhibitor resistant NF-κB activity has also been described in MCL.\textsuperscript{53} However, in ABC-DLBCL, an aggressive lymphoma having constitutive activation of NF-κB, bortezomib appeared to sensitize cells to combination chemotherapy\textsuperscript{91} suggesting that NF-κB inhibition may play a role in some tumors but not others.

**WNT pathway**

WNT signaling can occur through two major mechanisms; a canonical pathway through β-catenin (Figure 5A) and an alternative pathway leading to JNK activation. The canonical pathway is considered to be more relevant in cancer.\textsuperscript{92} Microarray analysis provided a first indication that the WNT pathway may be activated in MCL.\textsuperscript{40} Recently, nuclear expression of transcriptionally active β-catenin has been detected in MCL cell lines and tumor biopsies and correlated with GSK3β inactivation.\textsuperscript{93} WNT3 and WNT10a are consistently expressed in MCL cell lines and patient biopsies, and amplification of WNT11 on 11q13.4-q13.5 has been found in MCL cell lines. High expression of several FZD receptors and LRP5 has been documented indicating a possible autocrine loop of WNT signals. Furthermore, the serine-threonine kinase CK2, which is constitutively phosphorylated in MCL,\textsuperscript{38} phosphorylates β-catenin at Thr393, thereby impeding its proteasomal degradation. The resultant stabilization of β-catenin increases its transcriptional activity. Inhibition of the canonical pathway by siRNA mediated knockdown of DVL2 and FZD2, or by the pharmacologic agent quercetin reduced proliferation and induced apoptosis.\textsuperscript{46, 94}

**Hedgehog pathway**

Recent studies have suggested that stromally produced hedgehog (HH) proteins Indian (IHH), sonic (SHH), and desert (DHH) have a role in the proliferation of hematopoietic stem cells, lymphoid cells, and in B-cell malignancies.\textsuperscript{95} The molecules associated with SHH-signaling (Figure 5B) and its target transcripts PTCH, GLI1, and GLI2 are overexpressed in MCL primary cells compared to normal B cells. Interestingly GLI is located at 12q13, and may be co-amplified with CDK4 and MDM2 in some tumors.\textsuperscript{45} Activation of PTCH by SHH may increase proliferation of MCL cells, an effect that could be inhibited by cyclopamine, a specific inhibitor of SHH-GLI signaling. Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides significantly reduced cyclin D1 and BCL-2 transcript levels, decreased proliferation of MCL cells, and increased their susceptibility to
chemotherapy.96 These results indicate a role for SHH-GLI signaling in MCL proliferation, and identify the hedgehog pathway as a potential therapeutic target in MCL

**Antiapoptotic BCL-2 family proteins**

BCL-2 family proteins are key regulators of apoptosis, determining cellular fate in response to numerous insults (Figure 6).97 The BCL-2 pathway is deregulated in MCL; high-level copy number gains of the *BCL2* locus at 18q21.3 are frequent,31 high MCL1 expression is common in more aggressive tumors98 and can be increased by AKT/mTOR signaling, and BCL-XL overexpression has been linked to constitutive activation of the NF-κB pathway.89 Furthermore, the proapoptotic BH3-only protein BIM is frequently inactivated through genomic deletions of the *BCL2L11* gene. Homozygous deletions of the *BCL2L11* locus are found in MCL cell lines (Jeko, Z138, SP53, UPN1, SP-49), and IHC on tissue arrays demonstrated absence of BIM expression in 32% of primary tumors.4, 99

**Targeting BCL-2 family members to restore apoptosis:** the recognition of the importance of the BCL-2 family proteins in cancer has sparked efforts to target these critical survival molecules. One approach has been to reduce BCL-2 expression with compounds affecting gene or protein expression.100 A BCL-2 antisense oligonucleotide, oblimersen,101 has undergone extensive clinical testing in various malignancies, including MCL.102 However, despite encouraging pre-clinical data, and some activity in clinical trials, the compound has repeatedly failed to gain FDA approval100 and clinical trial activity has virtually stopped.90 Also oblimesen contains CpG motifs and acts as a TLR9 ligand giving rise to many effects beyond BCL-2 inhibition.100 The disappointing activity of oblimesen may be due to pharmacokinetic issues and/or redundancy within the BCL-2 system that makes inhibition of BCL-2 alone not very effective. A different strategy that may overcome this later limitation is based on small molecules directly inhibiting the function of BCL-2 antiapoptotic proteins. Several compounds have been isolated or chemically synthesized that mimic the action of BH3-only proteins and thereby promote apoptosis. Several such BH3-mimetics (ABT-737 (oral compound in clinical trials is ABT-263), AT-101, GX15-070) have shown in vitro and in vivo activity, both as single agents and in combination with proteasome inhibitors or conventional chemotherapy.103-105 BH3-mimetic compounds differ in their specificity and affinity for various BCL-2 family members.106 GX15-070 and AT-101 are considered pan-BCL-2 inhibitors and can antagonize MCL-1, which is upregulated by proteasome inhibition. Thus, combination of these compounds with bortezomib yields synergistic anti-tumor
activity. In contrast, ABT-737 does not neutralize MCL-1 or A1/BFL-1, high expression of which may cause resistance to this BH3-mimetic.

The microenvironment in MCL pathogenesis and immunomodulatory drugs

The microenvironment has been found to play an important role in the biology of several B-cell malignancies. There are some indications that tumor host interactions might be more important in MCL than is currently appreciated. First, MCL almost invariably involves the gastrointestinal tract, often only microscopically, but large tumors growing in the intestinal wall may cause presenting symptoms. This suggests that microenvironment factors determine disease localization and/or promote tumor cell expansion at these sites. Second, in vitro studies show that MCL cells interact with Bone Marrow Stromal Cells (BMSC) and these interactions can contribute to chemoresistance. Third, gene expression profiling revealed increased expression of factors involved in cell-cell crosstalk such as CCL4 and TNFSF9 (4-1BB-L) in MCL cells compared to normal B-cells. An intriguing observation is that cell adhesion to bone marrow stroma cells can decrease the proteasomal destruction of the cell cycle inhibitor p27 leading to reversible growth arrest. Such a “dormant” state could protect cells from cytotoxic therapy and may provide an explanation how rapidly proliferating MCL tumors can remain in remission for years before relapsing again as a highly proliferative cancer.

The immunomodulatory drugs (IMiDs), thalidomide and lenalidomide are active in MM. While the precise mechanism of action is not understood, effects on the microenvironment either by disruption of tumor-stroma interactions or through activation of immune effector mechanisms are hypothesized to contributed to the therapeutic effect. Recently, lenalidomide has been shown to improve formation of so-called “immune synapses” between CLL cells and autologous T-cells, which could enhance immune mediated anti-tumor effects. Phase II studies of single agent lenalidomide in lymphoma have yielded promising results in MCL (Table 2). In the NHL-002 study lenalidomide induced responses in 53% of 15 heavily pre-treated patients. The PFS of 5.6 and the median DOR of 13.7 months compares favorably to other treatment options for these patients. In the international NHL-003 study the response rate in 57 MCL patients was 42% with a median PFS of 5.7 months. A study of thalidomide in combination with rituximab found a response rate of 81% and a PFS of 20 months in 16 patients with relapsed MCL. Despite these encouraging results no follow up study using this combination has been reported.
Epigenetic regulation of tumor biology

In contrast to the detailed profiling of genetic lesions in MCL, epigenetic changes have only recently begun to be explored. Acetylation of histones leads to an open chromatin conformation that facilitates the access of transcription factors to DNA. In contrast, methylation of gene promoters can silence gene expression. Both acetylation and methylation can be altered in tumors and contribute to disease pathogenesis. A recent study of DNA methylation in primary MCL identified several genes that were hypermethylated and thereby silenced in tumor cells as compared to normal B-cells.116, 117 The DNA methyltransferase inhibitor decitabine not only reversed the aberrant hypermethylation, but synergized with a histone deacetylase inhibitor (HDACi) and induced cytotoxicity.116 Several hypomethylated and thereby upregulated genes could play a pathogenic role including NOTCH1, CDK5, and HDAC1. Surprisingly the frequently observed methylation of p15(INK4b) did not correlate with increased tumor proliferation.117

HDAC inhibitors: Hypoacetylation of histones is found in lymphomas compared to normal lymphoid tissue and data suggests that transformed cells are more sensitive to HDAC inhibition than normal cells.118 Studies with MCL cell lines have shown that SAHA, the only HDACi currently approved by the FDA, induces histone acetylation, upregulates p21 and p27, causes cell cycle arrest, and induces apoptosis. Interestingly, SAHA also reduced cyclin D1 expression at the protein but not mRNA level, through an unexpected inhibition of the PI3K/AKT/mTOR pathway.119

There is compelling evidence that HDACis also affect the handling of misfolded proteins. HDAC6 is a key factor in the aggresome pathway, a proteasome-independent pathway of protein degradation. The aggresome pathway is upregulated in response to proteasome inhibition, suggesting that simultaneous inhibition of both degradation pathways may results in an improved therapeutic effect. In this regard, preclinical data indicated a synergistic interaction between SAHA and bortezomib resulting in increased ROS generation and apoptosis.120

Heat shock proteins, chaperones of tumor biology, and HSP90 inhibitors

Heat shock proteins (HSP) are ubiquitously expressed chaperones that facilitate and guard the proteome from misfolding and aberrant aggregation. HSP90 is of particular interest because many of its clients are oncogenic signaling proteins including cyclin D1, c-MYC, p53, CDKs, AKT, IκB kinases, and survivin. HSP90 inhibitors displace the client proteins and target them for destruction by the proteasome system.121 Resultant depletion of essential oncoproteins can
induce cell cycle arrest and apoptosis. HSP90 in tumor cells is present entirely in active, complexed form rendering cancer cells more sensitive to HSP90 inhibitors than normal cells. HSP90 inhibitors have been a focus of drug development for over 10 years but no compound of this class has gained clinical approval. The first generation of HSP90 inhibitors 17-AAG and 17-DMAG are derivatives of the natural product geldanamycin. Most clinical trials used 17-AAG demonstrating moderate anti-tumor activity, which in part may be due to poor water solubility. Additional 17-AAG derivatives and several synthetic HSP90 inhibitors have been developed and could overcome some of the limitations of the older compounds. HSP90 inhibitors may be of particular value in combination with proteasome inhibitors. For example, IPI-504 synergized with bortezomib in a MM xenograft model, and is active against bortezomib resistant MCL cells possibly due to downregulation of the ER chaperone BIP/GRP78. An intriguing feature of this combination is that HSP90 inhibitors may reduce the neurotoxicity observed with bortezomib.

**Outlook**

Progress is being made! While median survival of MCL has typically been in the range of 3-4 years, recent series have reported 5-7 years. In addition to the introduction of dose intensified regimens, the advent of effective salvage treatments has likely made a major impact. To optimize the use of novel agents discussed in this review it will be imperative to incorporate comprehensive translational studies into clinical trials. It is worth keeping in mind that of the three classes of novel agents available for the treatment of relapsed patients, namely proteasome inhibitors, mTOR inhibitors, and lenalidomide, we still have only a limited understanding of their mechanisms of action and determinants of efficacy. In recent years MCL has been recognized as a heterogeneous disease with an extremely variable clinical course, making it essential to identify the patient subsets that are most likely to respond to distinct therapeutic approaches. Heading towards further improvement of therapy, the limiting step may be patient participation in well designed clinical trials, which incorporate comprehensive analyses of tumor samples. This is a prerequisite in order to unravel disease heterogeneity, develop predictive markers, and advance therapeutic options. Thus, MCL patients should be encouraged to enroll in clinical trials with a strong translational research program.
Acknowledgments: PPG and AW and their research are supported by the Intramural Research Program of the National Institutes of Health, the National, Heart, Lung and Blood Institute.

Author Contributions: P.P.G., M.D. and A.W. wrote the paper.

Conflict of Interest Disclosure: The authors have no conflicts of interest.
References


### Table 1. Selected recurrent genomic lesions in MCL

<table>
<thead>
<tr>
<th>Gene</th>
<th>Class/product</th>
<th>Function</th>
<th>Locus</th>
<th>Lesion&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cell cycle control and DNA damage pathways</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CCND1</strong></td>
<td>Cyclin D1</td>
<td>Forms holoenzyme with CDK4/CDK6 to regulate G1/S transition through Rb phosphorylation</td>
<td>11q13</td>
<td>+</td>
<td>31</td>
</tr>
<tr>
<td><strong>CDK4</strong></td>
<td>Cyclin dependent kinase</td>
<td>Forms complex with D-type cyclins to regulate early G1 phase</td>
<td>12q13</td>
<td>+</td>
<td>25</td>
</tr>
<tr>
<td><strong>BMI1</strong></td>
<td>Oncogene</td>
<td>Regulates cell cycle and senescence as a transcriptional repressor of INK4a/ARF locus.</td>
<td>10p11</td>
<td>+</td>
<td>25, 125</td>
</tr>
<tr>
<td><strong>MYC</strong></td>
<td>Oncogene</td>
<td>Induces mitogen independent cell proliferation. Often overexpressed in cancer</td>
<td>8q21</td>
<td>+</td>
<td>25</td>
</tr>
<tr>
<td><strong>MDM2</strong></td>
<td>Negative regulator of p53</td>
<td>E3 ligase for p53 targeting it for proteasomal degradation</td>
<td>12q13</td>
<td>+</td>
<td>126</td>
</tr>
<tr>
<td><strong>RB1</strong></td>
<td>Tumor suppressor</td>
<td>Binds to E2F1 preventing its nuclear translocation and cell cycle progression.</td>
<td>13q14.2</td>
<td>-</td>
<td>31, 127</td>
</tr>
<tr>
<td><strong>CDKN2C</strong></td>
<td>CDK inhibitor p18</td>
<td>Inhibits the activity of CDK/cyclin D complexes at G&lt;sub&gt;1&lt;/sub&gt;</td>
<td>1p32</td>
<td>-</td>
<td>31, 99</td>
</tr>
<tr>
<td><strong>CDKN2A</strong></td>
<td>CDK inhibitor encodes p14 and p16</td>
<td>Inhibit the activity of CDK/cyclin D complexes at G&lt;sub&gt;1&lt;/sub&gt;</td>
<td>9p21</td>
<td>-</td>
<td>128</td>
</tr>
<tr>
<td><strong>P53</strong></td>
<td>Tumor suppressor</td>
<td>Induces cell cycle arrest, apoptosis and senescence</td>
<td>17p13</td>
<td>-</td>
<td>25</td>
</tr>
<tr>
<td><strong>ATM</strong></td>
<td>Ser/Thr kinase of PI-3K family</td>
<td>After DNA damage ATM controls G&lt;sub&gt;1&lt;/sub&gt;/S and G&lt;sub&gt;2&lt;/sub&gt;/M cell cycle checkpoints by phosphorylation p53, Mdm2 and Chk2</td>
<td>11q22</td>
<td>-</td>
<td>129</td>
</tr>
<tr>
<td><strong>HIC1</strong></td>
<td>Tumor suppressor cooperates with p53</td>
<td>Loss of HIC1 results in deacetylation and inactivation of p53 by reduce DNA binding</td>
<td>17p13.3</td>
<td>-</td>
<td>130</td>
</tr>
<tr>
<td><strong>MOBKL2B</strong></td>
<td>Protein kinase</td>
<td>Essential for spindle pole body duplication and mitotic checkpoint regulation</td>
<td>9p21.2</td>
<td>-</td>
<td>31</td>
</tr>
<tr>
<td><strong>Signaling pathways</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SYK</strong></td>
<td>Tyr kinase</td>
<td>Involved in BCR signaling, mediates activation of PKCβ, NF-κB and PI3K-AKT pathways</td>
<td>9q22</td>
<td>+</td>
<td>37</td>
</tr>
<tr>
<td><strong>PIK3CA</strong></td>
<td>PI3K catalytic subunit α (p110α)</td>
<td>Sufficient to support survival of B-cells with defective BCR signaling, AKT activation</td>
<td>3q25</td>
<td>+</td>
<td>70</td>
</tr>
<tr>
<td><strong>FAF1</strong></td>
<td>Inhibitor of NF-κB activation</td>
<td>Suppresses IKK activity by binding to IKKβ resulting in p65 retention in the cytoplasm</td>
<td>1p32.3</td>
<td>-</td>
<td>31</td>
</tr>
<tr>
<td><strong>TNFAIP3</strong></td>
<td>A20. Tumor suppressor</td>
<td>Inhibits NF-κB activation through ubiquitin editing</td>
<td>6p23</td>
<td>-</td>
<td>88</td>
</tr>
<tr>
<td><strong>Apoptosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BCL2</strong></td>
<td>Key antiapoptotic regulator</td>
<td>Promotes cell survival by sequestering proapoptotic Bax and Bak</td>
<td>18q11-23</td>
<td>+</td>
<td>31</td>
</tr>
</tbody>
</table>

<sup>1</sup> Lesion type: + = gain, - = loss
| **BCL2L11** | BIM, BH3-only protein | Binds to BCL2, BCLXL and MCL1 acting as an apoptotic activator | 2q13 | 31, 99 |
| **Other pathways** |  |  |  |  |
| **PRAME** | Possible tumor antigen | Expressed in solid tumors and some hematopoietic neoplasias | 22q11.22 | 31 |
| **MAP2** | Microtubule stabilizer | Regulator of microtubule dynamics, cancer cell migration | 2q34 | 31 |
| **SP100** | Transcription factor | Localizes to nuclear bodies. Co-activator of HIPK2/p53-mediated transcription. | 2q37 | 31 |
| **MTAP** | Enzyme | Polyamine metabolism, frequently co-deleted with the p16 | 9p21.3 | 31 |

1(+), amplification; (-), deletion/mutation
Table 2. Novel treatment approaches in MCL in clinical development

<table>
<thead>
<tr>
<th>Mechanism of action and effects on MCL biology</th>
<th>Clinical development and results</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Reversible or irreversible inhibition of one or more proteasome activities.</td>
<td></td>
</tr>
<tr>
<td>- Cell cycle arrest and induction of apoptosis through oxidative and ER stress mediated upregulation of NOXA.</td>
<td></td>
</tr>
<tr>
<td><strong>CDK inhibitors:</strong> flavopiridol (pan-CDK), PD0332991(CDK4/6)</td>
<td>Flavopiridol (phase I, II): minimal responses as a single agent, modified dosing schedules may be more effective. PD0332991 (Phase I).</td>
</tr>
<tr>
<td>- flavopiridol: pan-CDK inhibitor, decreased RNA stability.</td>
<td></td>
</tr>
<tr>
<td>- PD0332991: blocks cyclin D1/CDK4 leading to cell cycle arrest.</td>
<td></td>
</tr>
<tr>
<td><strong>Serine/Threonine and Tyrosine kinase inhibitors:</strong> enzastaurin (PKC-β I), fostamatinib (SYK), PCI-32765(BTK)</td>
<td>Mostly stable disease for fostamatinib and enzastaurin. Objective responses in phase I study of PCI-32765.</td>
</tr>
<tr>
<td>- Inhibition of BCR signal transduction cascade</td>
<td></td>
</tr>
<tr>
<td>- Inactivation of AKT and mTOR</td>
<td></td>
</tr>
<tr>
<td>- Cell cycle arrest, cyclin D1 downregulation</td>
<td></td>
</tr>
<tr>
<td>- Activation of p53 and BAD-mediated apoptosis</td>
<td></td>
</tr>
<tr>
<td><strong>mTOR inhibitors (rapalog):</strong> rapamycin, temsirolimus (CCI-779), everolimus (RAD001), deforolimus (AP23573)</td>
<td>Temsirolimus (phase II and III): ORR 30-40% in relapsed patients, mostly PRs of rapid onset, (median 1 month), median duration of response of 6.9 months. Everolimus (phase I and II): some objective responses. Deferolimus (phase I): 30% PR and 40% SD</td>
</tr>
<tr>
<td>- Partial allosteric TORC1 inhibition.</td>
<td></td>
</tr>
<tr>
<td>- Cell cycle arrest; inconsistent effects on expression of cell cycle regulators (cyclin D1, p21, p27).</td>
<td></td>
</tr>
<tr>
<td>- May induce autophagy but not apoptosis.</td>
<td></td>
</tr>
<tr>
<td><strong>BH3 mimetics:</strong> *ABT-263, AT-101, obatoclax (GX15-070), Obatoclax (phase I and II) +/- bortezomib</td>
<td></td>
</tr>
<tr>
<td>- Inhibition of antiapoptotic members of BCL-2 family, BCL-2, BCL-X.L, GX 15-070 inhibits also MCL-1</td>
<td></td>
</tr>
<tr>
<td>- Mitochondrial depolarization through release of BH-3 only proteins and BAX/BAK activation</td>
<td></td>
</tr>
<tr>
<td><strong>IMIDs:</strong> lenalidomide, thalidomide</td>
<td>Lenalidomide (phase II): ORR 42-53%, CR 20%, PFS 5.6 months in relapsed MCL.</td>
</tr>
<tr>
<td>- Modulation of immune response</td>
<td></td>
</tr>
<tr>
<td>- Microenvironment or direct effect on tumor cells</td>
<td></td>
</tr>
<tr>
<td><strong>HDAC inhibitors:</strong> vorinostat (SAHA)</td>
<td>SAHA (phase I and II) +/- bortezomib</td>
</tr>
<tr>
<td>- Cyclin D1 downregulation, p21 and p27 upregulation, and cell cycle arrest.</td>
<td></td>
</tr>
<tr>
<td>- Upregulation of the BH-3 only proteins BIM and BMF</td>
<td></td>
</tr>
<tr>
<td>- Degradation of client proteins including cyclin D1, CDK4, IKKβ, AKT, c-MYC and c-RAF133</td>
<td></td>
</tr>
<tr>
<td>- Cell cycle arrest</td>
<td></td>
</tr>
<tr>
<td>- Activation of the mitochondrial apoptotic pathway</td>
<td></td>
</tr>
</tbody>
</table>

CT-L:chymotrypsin- like; T-L trypsin- like; C-L caspase-like

*ABT-263 is the oral formulation of the compound used in clinical trials; ABT-737 is the equivalent compound typically used in preclinical studies.

Information on ongoing clinical trials at http://clinicaltrials.gov

For personal use only.
Figure legends

Figure 1. Clinical and biologic characteristics of MCL. (A) MCL diagnosis is based on morphology and immunophenotyping (CD20+, CD5+, CD23-, FMC7+). Pathologic subclassification recognizes two major subsets: classic and blastoid. (B) FISH cytogenetics demonstrating translocation t(11:14)(q13;q32) and immunohistochemistry for detection of cyclin D1 overexpression are helpful adjuncts in the diagnosis of MCL. Immunohistochemistry images provided by Stefania Pittaluga; images of FISH testing provided by Diane C. Arthur. (C) Tumor proliferation determines outcome. Figure adapted from original with permission. The expression levels of 20 genes related to cell proliferation were summarized in the proliferating signature average. Lowest (green) to highest (red) expression of the proliferation signature average in lymph node biopsies from 92 MCL patients is shown over a 16-fold range. Kaplan-Meier analysis for patients grouped into four quartiles based on this score is shown. (D) CCND1 locus at 11q13 and cyclin D1 mRNA isoforms. Shaded boxes represent coding sequences, open boxes represent noncoding exon sequences. The 3'UTR of full length 4.5kb cyclin D1a contains binding sites for miRs (blue boxes) and AU-rich elements (red triangles); cyclin D1a isoforms with a truncated 3'UTR lack these elements. The alternatively spliced 1.7-kb cyclin D1b mRNA lacks exon 5 and retains part of intron 4. Illustration by Paulette Dennis.

Figure 2. Cyclin D1, at the crossroads of MCL pathogenesis. Cyclin D1 mRNA stability and translation is increased by the PI3K/AKT/mTOR pathway. Cyclin D1 translocates into the nucleus and forms a holoenzyme with CDK4/6 to phosphorylate the retinoblastoma protein (RB) resulting in release of E2F transcription factors and G1/S phase transition. In addition, cyclin D1/CDK4 complexes have kinase independent functions, notably binding of the cell cycle inhibitor p27kip, which is thereby titrated away from cyclinE/CDK2 complexes further promoting cell cycle progression. Cyclin D1/CDK4 inhibits degradation of CDT1, the rate limiting factor in DNA replication. Stabilization of CDT1 in S-phase can induce the replication of already transcribed chromosomal segments giving rise to increased number of double strand breaks and activation of DNA damage checkpoints. In S-phase cyclin D1 is phosphorylated on threonine 286 by GSK3β, exported from the nucleus by CRM-1, polyubiquitinated by the E3 ligase SCF(FBX4-αB Crystallin) and degraded through the proteasome (reviewed in 28). GSK3β is phosphorylated and inactivated by AKT and WNT signaling. Several components of this cell cycle control machinery are altered in MCL: blue symbols (Δ) indicate molecules inactivated or downregulated, red symbols indicate molecules activated or overexpressed. Illustration by Paulette Dennis.

Figure 3. Defective DNA damage responses in MCL. DNA damage activates the kinases ATM and ATR, together with p53 and p14/ARF, which can induce cell cycle arrest, DNA repair, or apoptosis. The E3-ubiquitin ligase MDM2 that targets p53 for proteasomal degradation is inhibited by ARF, which in turn is inhibited by BMI1. CHK1 and CHK2, activated by ATR and ATM respectively, phosphorylate key substrates (p53, CDC25A, CDC25B) leading to cell cycle arrest. Several steps in this DNA damage response are altered in MCL: blue symbols (Δ) indicate molecules inactivated or downregulated, red symbols indicate molecules activated or overexpressed. Illustration by Paulette Dennis.

Figure 4. BCR, NF-κB and PI3K/AKT/mTOR deregulation in MCL. BCR engagement induces SYK phosphorylation, which in turn activates phospholipase C-γ (PLC-γ) and protein kinase C-β (PKC-β). PI3K functions as a transducer of BCR signaling and can be activated by
SYK-dependent phosphorylation of CD19 and B-cell PI3K adaptor protein (BCAP). PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) on the plasma membrane to generate the second messenger, phosphatidylinositol-3,4,5-trisphosphate (PIP3). This process is reverted by the phosphatase and tensin homologue (PTEN). PI3K then phosphorylates PDK-1 and the serine/threonine kinase AKT (Thr308) that activates mTOR (by inactivation of the inhibitor TSC1/2) and NF-κB (by activation of IKK). Only the mTOR complex 1 (mTORC1) is under AKT control and activates cap-dependent translation through S6K and 4E-BP1. mTOR complex 2 (mTORC2) can phosphorylate AKT (Ser473) increasing its kinase activity. Canonical NF-κB activation through AKT, or PKC-β involves IKK mediated phosphorylation of the inhibitor IκBα resulting in its proteasomal degradation and release of bound transcription factors that can then translocate to the nucleus. A20 and FAF1 inhibit NF-κB activation. The alternative pathway is activated by phosphorylation of p100 by IKKα complexes and subsequent proteasomal generation of p52. The cytokine BAFF/BLyS by binding to BAFF-R activates both canonical and non-canonical pathways. NF-κB transcription factors form hetero- and homo-dimers to activate the transcription of genes involved in survival, proliferation and apoptosis. Several steps in these signaling pathways are altered in MCL: blue symbols (Δ) indicate molecules inactivated or downregulated, red symbols indicate molecules activated or overexpressed. Illustration by Paulette Dennis.

**Figure 5. Activation of WNT and Hedgehog pathways in MCL.** (A) In the absence of WNT ligand, β-catenin is actively degraded through a protein complex called the ‘destruction box’, where GSK3β phosphorylates β-catenin targeting it for degradation by the proteasome. Binding of WNT to Frizzled (FZD)–LRP receptor complexes at the membrane, induces the formation of Dishevelled (DVL)–FZD complexes that sequester Axin and GSK3β inhibiting the formation of the ‘destruction box’. This allows translocation of β-catenin to the nucleus where it dimerizes with TCF and LEF.134 (B) Binding of SHH to patched (PTCH), allows smoothened (SMO) to transduce a signal into the cytoplasm that leads to the breakdown of a protein complex formed by Fused, SUFU, and the transcription factor GLI. GLI is thereby released and translocates into the nucleus.135 Red symbols indicate molecules activated or overexpressed in MCL. Illustration by Paulette Dennis.

**Figure 6. The antiapoptotic phenotype and alterations in BCL-2 family members in MCL.** The prosurvival BCL-2 family members (BCL-2, BCL-XL, MCL-1, BCL-W and A1/BFL1) bind and sequester the apoptosis inducing members BAX and BAK. The BH3-only proteins (BIM, PUMA, NOXA, BAD, BID, BMF, BIK, and HRK) can be activated by cytotoxic signals and selectively engage prosurvival members, which leads to release of BAX and Bak leading to permeabilization of the mitochondrion, the release of proapoptotic factors, caspase activation and finally cell death.136, 137 BCL2L11/BIM is frequently deleted (blue symbol (Δ)) while some anti-apoptotic family members are commonly overexpressed (red symbols) in MCL including BCL-2. In addition PI3K/AKT/mTOR signaling can inactivate BAD through phosphorylation and stabilization of MCL-1 protein. Illustration by Paulette Dennis.
Figure 1

A. Lymph node biopsy
   - Classic
   - Blastoid
   - 400x
   - 1000x

B. FISH
   - Normal
   - t11;14
   - LN: Cyclin D1
     - 1000x

C. Mantle Cell Lymphoma Biopsies (n = 92)
   - Proliferation signature:
     - Genes
     - Average
     - Quartiles

D. Diagram showing:
   - Cyclin D1b
   - 11q13
   - Cyclin D1a
   - AAA
Figure 4
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

Patricia Pérez-Galán, Martin Dreyling and Adrian Wiestner